26774-38-9

Basic information

• Product Name: 3-chloro-N-1,3-thiazol-2-ylpropanamide
• Synonyms: 3-chloro-N-1,3-thiazol-2-ylpropanamide;AKOS BB416;ASISCHEM D51480;UKRORGSYN-BB BBV-031285;3-chloro-N-1,3-thiazol-2-ylpropanamide(SALTDATA: FREE);3-chloro-N-(2-thiazolyl)propanamide;3-chloro-N-thiazol-2-yl-propanamide;3-chloro-N-thiazol-2-yl-propionamide
• CAS NO: 26774-38-9
• Molecular Formula: C₆H₇ClN₂OS
• Molecular Weight: 190.65
• Mol File: 26774-38-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 169 °C
• Appearance: /
• Density: 1.432g/cm³
• Refractive Index: 1.615
• PKA: 8.83±0.50(Predicted)
• CAS DataBase Reference: 3-chloro-N-1,3-thiazol-2-ylpropanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-N-1,3-thiazol-2-ylpropanamide(26774-38-9)
• EPA Substance Registry System: 3-chloro-N-1,3-thiazol-2-ylpropanamide(26774-38-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 26774-38-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H7ClN2OS/c7-2-1-5(10)9-6-8-3-4-11-6/h3-4H,1-2H2,(H,8,9,10)

Upstream product

• 96-50-4 2-thiazolylamine 
• 625-36-5 2-chloropropionyl chloride 

Downstream Products

• 26865-75-8 S-2-(<2-(2-Thiazolylcarbamoyl)ethyl>amino)ethyl hydrogenthiosulfat 
• 39786-10-2 5,6-Dihydro-7H-thiazolo<3,2-a>pyrimidin-7-on 
• 76099-62-2 3-Diphenylamino-N-thiazol-2-yl-propionamide 
• 76099-65-5 3-Dibenzylamino-N-thiazol-2-yl-propionamide 
• 329210-40-4 C₁₆H₂₀N₄OS 

Relevant articles and documents

Synthesis, physicochemical characterization, cytotoxicity, antimicrobial, anti-inflammatory and psychotropic activity of new N-[1,3-(benzo)thiazol-2-yl]- ω-[3,4-dihydroisoquinolin-2(1H)-yl]alkanamides

A series of new N-[(benzo)thiazol-2-yl]-2/3-[3,4-dihydroisoquinolin-2(1H)- yl]ethan/propanamide derivatives was synthesized and characterized by 1H, 13C NMR and IR spectroscopy and mass-spectrometry. A single crystal X-ray study of N

Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors

DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions.

Synthesis and biological evaluation of new thiazolyl/benzothiazolyl-amides, derivatives of 4-phenyl-piperazine

A series of thiazolyl-N-phenyl piperazines has been synthesised and tested for anti-inflammatory activity. Their RM values were determined as an expression of their lipophilicity. Theoretical calculation of their lipophilicity, as clog P and logPsk also performed. The effect of the synthesised compounds on inflammation, using the carrageenin induced mouse paw oedema model was studied. In general, the studied compounds were found to be potent anti-inflammatory agents (44-74.1%). Anti-inflammatory activity was influenced by some structural characteristics of the synthesised compounds. An attempt was made to correlate their biological activity with some physicochemical parameters using a quantitative structure-activity relationship approach (QSAR).